FDA Panel Votes on Pimavanserin for Alzheimer Disease Psychosis
The Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee voted 3 “yes” and 9 “no” on whether the available evidence supports the conclusion that pimavanserin is effective for the treatment of hallucinations and delusions…